By proceeding, you agree to our Terms of Use and Privacy Policy.
Chief Scientific Officer
#biopharmaceuticals #meeting #immunogenicity
#Europe
Andrea Hawe is working towards outlining the application of particle analytics for different types of biopharmaceuticals and particle size ranges. She often talks on the influence of critical quality
Senior Scientist
#immunogenicity #molecularbiology
Chloé Ackaert is a pharmacist by training (Catholic University of Leuven 2009) and obtained her PhD at the University of Salzburg (Austria) for the research on the impact of nitration on the immunogen
Director, Analytical Development
#immunogenicity #anti-drug #autoantibodies #neutralizing
#NorthAmerica
ssay development/validation/method transfer specialist with extensive experience with immunogenicity (drug, anti-drug, autoantibodies, neutralizing/functional) and analytical assays (host cell protein
Principal Scientist II
#immunogenicity #immunology
Michael is a trained immunologist specialized in immunogenicity profiling with over 6 years of expertise in immunogenicity risk assessment of biologics. He joined Novartis in 2017, applying his expert